MD-PATTON-ELECTRONICS
31.5.2016 15:16:46 CEST | Business Wire | Press release
Patton Electronics —US manufacturer of UC, cloud, and IoT enabling solutions for carrier, enterprise and industrial networks—is now shipping the SmartNode OpenScape Business Appliance (SN-OSB).
Developed in partnership with Unify , Patton’s SN-OSB, offers small-to-medium businesses (SMBs) a one-box unified communications (UC) solution for up to 1,000 users that is fast and easy to implement.
While many smaller companies have been reluctant to make the transition to Unified Communications, Patton and Unify offer a solution that makes it fast and easy for the information technology (IT) staff of SMBs to implement an All-IP solution.
“Demand is pretty hot for this product,” said Miklos Szabo, product manager for the SN-OSB. “There’s already a significant backlog. So we encourage interested partners to order early to ensure timely fulfillment.”
>>For questions or additional information contact the product manager…
The SN-OSB appliance combines Patton’s SmartNode VoIP-gateway technology and hardware manufacturing expertise with Unify’s OpenScape Business S unified communications software to offer an affordable, state-of-the art UC solution for SMBs in a single device.
OpenScape Business S—the new-generation Unified Communications and Collaboration (UCC) software from Unify (which combines the best of HiPath 3000 and OpenScape Office and plays well with OpenStage IP phones) comes factory-installed and ready to go.
Unlike most UC appliances, the SN-OSB offers built-in telephony interfaces (PRI, BRI, FXS, and FXO) that connect legacy devices with All-IP UCC services, while supporting SIP Trunks, TDM Trunks and TDM or dual-SIP survivability with assured interoperability among all systems.
The one-box UCC solution from Patton and Unify is based on Patton’s SmartNode Open Gateway Appliance (SNOGA) hardware platform, which is able to integrate any existing analog, PBX, digital PBX, or DECT phone system with all SIP-based devices and UCC services.
For companies needing a VoIP-gateway solution for their OpenScape implementation, Unify has certified SmartNode VoIP gateways, IADs, and eSBCs for interoperability with its OpenScape Business software.
In related news, Novum Networks is now rolling out its business-class NBN service (based on Broadsoft BroadWorks hosted telephony) that features Patton’s SmartNode VoIP products as CPE solutions.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160531005492/en/
Contact:
For Patton Electronics:
Glendon Flowers, 301-975-1000
press@patton.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ Expands ConnectAI Charter Program with Mars Snacking22.10.2026 12:45:00 CEST | Press release
Mars joins a growing group of global companies working with NIQ forward-deployed engineers to bring proprietary consumer and market intelligence into enterprise AI workflows NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced Mars as a new ConnectAI Charter client, expanding the program’s growing roster of global companies working with NIQ to build the intelligence foundation for amplifying enterprise AI workflows. Through the ConnectAI Charter Program, NIQ forward-deployed engineers and data scientists are working with Mars to embed NIQ intelligence in the expansion of AI-enabled workflows across its business. The engagement focuses on connecting NIQ data, models, and business context with Mars’ AI ecosystem to help reduce the distance between data and decision-making. Together, they are tackling use cases like conversational analytics and harmonized product data to lay the foundation for future use cases. “As we expand the use of AI across our business, we
Spotlight Medical Announces Successful Independent Evaluation of Its Digital Slide-Based Test for Assessing Recurrence Risk in Early Breast Cancer22.10.2026 12:18:00 CEST | Press release
An independent, blinded evaluation of 620 patients from the phase III PANTHER trial identified nearly one-quarter as Low Risk despite clinically high-risk breast cancer, with favorable ten-year outcomes. Spotlight Medical, a company developing AI-powered prognostic tests in oncology, today announced results from an independent evaluation of myStage Dx, its CE-IVDR-marked test for assessing recurrence risk in patients with hormone receptor-positive, HER2-negative early breast cancer. The study was conducted by researchers at Karolinska Institutet in Sweden. Independent, Blinded Evaluation Using Phase III Trial Data The study used data from 620 patients enrolled in PANTHER, an international randomized phase III trial comparing dose-dense with standard chemotherapy. myStage Dxpredictions were generated blinded to clinical outcomes. Researchers at Karolinska Institutet linked the predictions to patient outcomes and independently assessed prognostic performance according to a prespecified p
Zoomtopia: Zoom lancerer nye AI-funktioner22.10.2026 12:13:00 CEST | Pressemeddelelse
Zoom vil forkorte vejen fra mødebeslutning til udført arbejde. På konferencen Zoomtopia præsenterer virksomheden Unified Context Layer – et fælles informationslag, der forbinder samtaler, dokumenter og data, så AI kan forstå sammenhængen og hjælpe med de næste skridt. Samtidig lanceres flere nye AI-produkter og -funktioner, der skal gøre det lettere at omsætte diskussioner og beslutninger til handling. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20261021318859/da/ I møder og samtaler træffes vigtige beslutninger, og virksomheder får værdifuld indsigt i deres kunder. En kundedialog kan begynde i et møde, fortsætte i telefonen og derefter gå over i en chat. Når informationen spredes mellem forskellige værktøjer, bliver det svært for både medarbejdere og AI-agenter at få et samlet billede af, hvad der er blevet sagt og besluttet. Resultatet er, at værdifuld tid går med at finde ud af, hvad der er blevet sagt og besluttet, og
TACTICAAI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron22.10.2026 12:01:00 CEST | Press release
Collaboration brings together TACTICAAI’s operational decision-intelligence technology and NVIDIA AI capabilities to advance reasoning, autonomous analysis and video intelligence for real-world deployment TACTICAAI, an operational decision-intelligence company, today announced a collaboration with NVIDIA to advance and scale the deployment of agentic AI capabilities. The companies will work together to integrate and optimize NVIDIA Nemotron models within TACTICAAI’s multi-intelligence platform, with a focus on expanding these capabilities and supporting deployment with major customers internationally. The collaboration was announced at NVIDIA GTC Berlin. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022054475/en/ TACTICA AI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron (Graphic: AETOSWire) The collaboration with NVIDIA builds on the company’s existing technology, integrating selected NVIDIA
BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 522.10.2026 12:01:00 CEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2026 financial results on Thursday, November 5, 2026, before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com.To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom